Precision radiation medicine company Elekta AB (STO:EKTAB) announced on Monday the award of a group purchasing agreement for full line radiation oncology products and services to Premier.
Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,000 US hospitals and 175,000 other providers to transform healthcare.
Effective 1 September 2019, this new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for linear accelerators (linacs), Elekta Unity MR-linac, oncology informatics and services. The agreement implies that Premier will be the exclusive provider of precision radiation solutions to its extensive network of healthcare systems, hospitals and clinics.
This five-year sole source agreement with Elekta, effective from 1 September 2019, will enable Premier's members to begin purchasing Elekta's advanced oncology solutions, including Elekta Unity, a state-of-the-art MR-linac; Leksell Gamma Knife, bringing precision radiation medicine to the treatment of brain metastasis, as well as other brain tumours and functional brain disorders; Versa HD, a highly versatile, all-in-one radiotherapy system that overcomes the complexity of stereotactic treatments with high definition dynamic radiosurgery (HDRS); Elekta Infinity, a multifunctional platform, combining superior dose conformance and advanced image guidance; MOSAIQ Plaza, Elekta's patient-centric, integrative software suite and Elekta Care, a proactive services programme that helps customers deliver exceptional care.
Elekta Unity has CE mark and 510(k) clearance but is not available in all markets, the company added.
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories